14th May 2021
Sleepiz AG, a Swiss medical technology start-up, have announced that it has received $500k funding to enable the future of sleep diagnostics through novel three-dimensional radar technology.
Funded by the European Union’s HORIZON 2020 EUROSTAR grant, Sleepiz AG are collaborating with Acconeer, a Swedish radar sensor company, and working in partnership with University of Gothenburg’s Sleep Medicine Center. A total of $1M has been granted for the research between Sleepiz and Acconeer.
Sleepiz, who were winners of the EIT Health Headstart programme and the regional EIT Health Catapult in Germany, has recently entered the market with its first medical device, the Sleepiz One. The deviced, designed to help people who suffer from sleep apnea manage their condition, operates in a non-contact fashion and measures movements originating from heart contractions and breathing patterns, as well as body motions with medical-grade accuracy.
By combining expertise in both medical and radar industries, the collaboration will develop the next generation of contactless devices. The radar aims to enable better personalised therapy through a novel three-dimensional monitoring approach, providing more insights and standards than current state of the art devices. The project is due to begin in May 2021 and will be carried out for three years.
“For Sleepiz, such recognition and trust by the European Union, allows to envision the future of healthcare that is deeply rooted in the power of medicine and technology combined. Our goal for this collaboration with Acconeer and University of Gothenburg is to continuously progress the status quo and create the next generation of our sleep monitoring device that will improve people’s lives with the most innovative technology available. All at the comfort of one’s home.” says Soumya Dash, the CEO and co-founder of Sleepiz AG.
EIT Health Catapult 2021 selects 42 semi-finalists
Learn about these promising start-ups
EIT Health partners Warsaw Health Innovation Hub
A joint initiative between government and business
Will COVID-19 spark a cancer vaccine boom?
Using DNA vaccines to fight cancer